2026-09-08T11:45:55Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/58142021-11-02T12:07:55Zcom_10259_4365com_10259_5086com_10259_2604col_10259_4366

Ortega, Enrique Pérez Arnáiz, Cristina Rodríguez, Venancio Janiak, Christoph Busto Vázquez, Natalia García Ruiz, Begoña Ruiz, José 2021-06-24T08:14:52Z 2021-06-24T08:14:52Z 2021-10 0223-5234 http://hdl.handle.net/10259/5814 10.1016/j.ejmech.2021.113600 Cancer and antibiotic resistance are two global health threats that usually hamper clinical chemotherapeutic efficacy. Particularly for lung cancer, bacterial infections frequently arise thereby complicating the course of cancer treatment. In this sense, three new neutral luminescent cycloplatinated(II) photosensitizers of the type [Pt(dmba)(L)] (dmba = N,N-dimethylbenzylamine-κN,κC; L = 2-(benzo[d]oxazol-2-yl)-phenolato-κN,κO 1, 2-(benzo[d]thiazol-2-yl)-phenolato-κN,κO 2, and 2-(1-methyl-1H-benzo[d]imidazole-2-yl)phenolato-κN,κO 3) have been characterized and developed to potentially eliminate both resistant bacteria and lung cancer cells. The phototherapeutic effects of complex 2 have been evaluated using low doses of blue light irradiation. Complex 2 exerted promising photoactivity against pathogenic Gram-positive bacteria strains of clinical interest, displaying a phototoxic index (PI) of 15 for methicillin-resistant Staphylococcus aureus, one of the major microorganisms predominating lung infections. Likewise, the anticancer activity of 2 was also increased upon light irradiation in human lung A549 cancer cells (PI = 36). Further in vitro experiments with this platinum(II) complex suggest that ROS-generating photodynamic reactions were involved upon light irradiation, thus providing a reasonable mechanism for its dual anticancer and antibacterial activities. Spanish Ministerio de Ciencia e Innovación (MCI/AEI) and FEDER funds (Projects RTI2018-096891-B-I00, RTI2018-102040-B-100 and MultiMetDrugs network RED2018-102471-T), Consejería de Educación-Junta de Castilla y León-FEDER (BU042U16-BU305P18), “la Caixa” Banking Foundation (LCF/PR/PR12/11070003) and Fundación Séneca-Región de Murcia (Project 20857/PI/18). E.O. thanks AECC (PRDMU19003ORTE). Networking support by the COST Action CA18202 application/pdf eng Elsevier European Journal of Medicinal Chemistry. 2021, V. 222, 113600 https://doi.org/10.1016/j.ejmech.2021.113600 info:eu-repo/grantAgreement/MICINN/RTI2018-096891-B-I00 info:eu-repo/grantAgreement/MICINN/RTI2018-102040-B-100 info:eu-repo/grantAgreement/MICINN/RED2018-102471-T info:eu-repo/grantAgreement/JCyL/BU042U16-BU305P18 info:eu-repo/grantAgreement/FundaciónLaCaixa/LCF/PR/PR12/11070003 info:eu-repo/grantAgreement/FundaciónSeneca/20857/PI/18 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Platinum(II) complexes Anticancer and antibacterial activity Photodynamic inhibition Photodynamic therapy Dual action agents Química física Chemistry, Physical and theoretical A 2-(benzothiazol-2-yl)-phenolato platinum(II) complex as potential photosensitizer for combating bacterial infections in lung cancer chemotherapy† info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion European Journal of Medicinal Chemistry 222 113600